ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no

ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no

Source: 
Fierce Pharma
snippet: 

Back in January, Merck said Keytruda—its anti-PD-1 therapy—had missed the mark in an area where two of its rivals had succeeded. Both those rivals are anti-PD-L1 treatments, so could that PD-1/PD-L1 difference be the reason? The New Jersey drugmaker doesn’t think so.